The nurse is preparing to assist with blood collection on a newly admitted patient who has been taking phenytoin for several years.
The provider has ordered a complete blood count and liver function tests.
Which other blood test will the nurse discuss with the provider?
Coagulation studies.
Serum electrolytes.
Renal function tests.
Blood glucose.
The Correct Answer is D
Choice A rationale
Coagulation studies assess the blood's ability to clot and are not directly related to the monitoring of phenytoin therapy. These tests are more relevant for patients with bleeding disorders or those on anticoagulant therapy.
Choice B rationale
Serum electrolytes, including levels of sodium, potassium, and calcium, are important for overall health but are not specifically indicative of phenytoin levels. Phenytoin may affect calcium metabolism, but it is not the primary focus for routine monitoring.
Choice C rationale
Renal function tests are crucial for assessing kidney function but do not directly monitor phenytoin therapy. Phenytoin is primarily metabolized in the liver, making liver function tests more relevant.
Choice D rationale
Blood glucose levels should be monitored in patients taking phenytoin as the drug can cause alterations in blood glucose levels. Both hypoglycemia and hyperglycemia have been reported, so it is important to check glucose levels to ensure they remain within a normal range.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is C
Explanation
Choice A rationale
Working with animals is typically done in preclinical trials before phase I studies in humans and is not part of phase III drug evaluation studies.
Choice B rationale
Conducting research to determine the effectiveness of the drug is part of phase II studies. Phase III studies focus more on confirming effectiveness, monitoring side effects, and comparing it to commonly used treatments.
Choice C rationale
Monitoring and observing patients closely for adverse effects is a key responsibility in phase III drug evaluation studies. These studies involve a larger patient population to gather comprehensive safety and efficacy data.
Choice D rationale
Choosing appropriate patients to be involved in the study is primarily the responsibility of researchers and clinicians during the earlier phases of drug development, such as phase I and phase II studies.
Correct Answer is A
Explanation
Step 1 is (120 mL ÷ 60 min) × 15 gtt/mL.
Step 2 is (2 mL/min) × 15 gtt/mL.
Step 3 is 30 gtt/min.
Final calculated answer is 30 gtt/min.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.